Copyright
©The Author(s) 2015.
World J Gastroenterol. Nov 21, 2015; 21(43): 12311-12321
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12311
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12311
Anti-HCV DAA | cART not recommended | Dose changes |
Boceprevir | Atazanavir | |
Darunavir/ritonavir | ||
Efavirenz | ||
Ritonavir | ||
Telaprevir | Darunavir | Efavirenz - dose increased |
Lopinavir/ritonavir | to 1125 mg TDS | |
Simeprevir | Atazanavir | |
Efavirenz | ||
Darunavir/ritonavir | ||
Nevirapine | ||
Daclatasvir | - | Efavirenz - dose increased to 90 mg OD |
Atazanavir and protease inhibitors - dose reduced to 30 mg OD | ||
Sofosbuvir | Didanosine | |
Zidovudine |
- Citation: Joshi D, Agarwal K. Role of liver transplantation in human immunodeficiency virus positive patients. World J Gastroenterol 2015; 21(43): 12311-12321
- URL: https://www.wjgnet.com/1007-9327/full/v21/i43/12311.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i43.12311